To Jump Start China, Think Commercial: Amgen Ties Knot With Beta Pharma For Vectibix
This article was originally published in The Pink Sheet Daily
Executive Summary
Since fixing its eyes on China, Amgen has been scouting the country for deals. Now the first result is in, a JV with local industry darling Beta Pharma to commercialize Vectibix in China.
You may also be interested in...
Deals of the Week: Options Abound As Forest Keeps Its Eyes On A Prize-Winner
Reflecting a long trend, three of this past week’s deals include option arrangements, including one with a new twist. Also, a rare disease partnership between Shire and Atlas Venture finally leads to a deal and Takeda continues building its vaccines business.
Insider Analysis From Easton Associates: Are Patient Assistance Programs The Silver Bullet To Meet Affordability Challenges In China?
By Celia Deng, Zhiyi Tong and Paul Zhang
Lilly Snatches ImClone Away From Bristol
Lilly’s $6.5 billion acquisition of ImClone will create an oncology “powerhouse” with 18 cancer drugs in clinical development.